ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.72
0.20%
US Tech 100
20,897.20
-1.35%
S&P 500
5,970.84
-1.11%
US Dollar vs CAD
1.44175
-0.01%
Bitcoin
94,247.84
0.09%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Caladrius Biosciences Inc (CLBS) Share Price

Caladrius Biosciences Inc

Caladrius Biosciences Inc (CLBS)

Celebrus Technologies Plc
0.4264
0.00
(0.00%)
Closed December 28 3:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.4264
Bid
0.4264
Ask
0.43
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
3.475M
Previous Close
0.4264
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
8,150,000
Dividend Yield
-
PE Ratio
-1.18
Earnings Per Share (EPS)
-2.56
Revenue
-
Net Profit
-20.84M

About Caladrius Biosciences Inc

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the... Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its current product candidates include XOWNA, HONEDRA and CLBS201. Show more

Sector
Health & Allied Services,nec
Industry
Insurance Carriers, Nec
Website
www.caladrius.com
Headquarters
Wilmington, Delaware, USA
Founded
2006

Ask ADVFN Intelligence (AI)

CLBS Latest News

More News

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens...

September 15 2022
GlobeNewswire Inc.

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified...

September 14 2022
GlobeNewswire Inc.

Life Sciences Virtual Investor Conference Agenda Announced for September 15th

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual...

September 12 2022
GlobeNewswire Inc.

Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing...

September 08 2022
GlobeNewswire Inc.

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius’ initial...

August 10 2022
GlobeNewswire Inc.

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins...

August 04 2022
GlobeNewswire Inc.

Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

BASKING RIDGE, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

August 02 2022
GlobeNewswire Inc.

Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

July 28 2022
GlobeNewswire Inc.

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology

BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company...

July 06 2022
GlobeNewswire Inc.

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...

June 09 2022
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

CLBS - Frequently Asked Questions (FAQ)

What is the current Caladrius Biosciences share price?
The current share price of Caladrius Biosciences is US$ 0.4264
How many Caladrius Biosciences shares are in issue?
Caladrius Biosciences has 8,150,000 shares in issue
What is the market cap of Caladrius Biosciences?
The market capitalisation of Caladrius Biosciences is USD 3.48M
What is the 1 year trading range for Caladrius Biosciences share price?
Caladrius Biosciences has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Caladrius Biosciences?
The price to earnings ratio of Caladrius Biosciences is -1.18
What is the reporting currency for Caladrius Biosciences?
Caladrius Biosciences reports financial results in USD
What is the latest annual profit for Caladrius Biosciences?
The latest annual profit of Caladrius Biosciences is USD -20.84M
What is the registered address of Caladrius Biosciences?
The registered address for Caladrius Biosciences is 651 N BROAD ST SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19709
What is the Caladrius Biosciences website address?
The website address for Caladrius Biosciences is www.caladrius.com
Which industry sector does Caladrius Biosciences operate in?
Caladrius Biosciences operates in the INSURANCE CARRIERS, NEC sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
INTZIntrusion Inc
US$ 2.167
(381.56%)
189.59M
AILEiLearningEngines Inc
US$ 0.5932
(267.31%)
563.26M
HUBCWHub Cyber Security Ltd
US$ 0.035
(250.00%)
2.79M
GTIGraphjet Technology
US$ 0.967551
(185.83%)
398.95M
LITMSnow Lake Resources Ltd
US$ 1.61
(82.95%)
131.98M
NEUPNeuphoria Therapeutics Inc
US$ 4.11
(-92.30%)
940.73k
VIRXViracta Therapeutics Inc
US$ 0.16
(-32.49%)
9.47M
PRFXPainReform Ltd
US$ 3.48
(-28.98%)
949.52k
AIREreAlpha Tech Corporation
US$ 2.56
(-28.49%)
8.42M
AVGRAvinger Inc
US$ 0.9721
(-24.05%)
2.16M
AILEiLearningEngines Inc
US$ 0.5932
(267.31%)
563.26M
GTIGraphjet Technology
US$ 0.967551
(185.83%)
398.95M
RGTIRigetti Computing Inc
US$ 17.08
(10.62%)
305.79M
XTIAXTI Aerospace Inc
US$ 0.03935
(-1.63%)
268M
QSIQuantum Si Inc
US$ 3.585
(66.74%)
256.01M

Discussion

View Full Feed
JustJack JustJack 5 minutes ago
Not much, if anything, to laugh about with this share selling scheme. 

Unless you are Steve or Alexoops I guess.  
AITX
YY1000 YY1000 7 minutes ago
There are two reasons cited for why the '953 patent cannot claim priority date from the '048 provisional: (1) the change from C2 to C1 (which ENTA argued was correcting a typographical error) and (2) "the disclosure of a broad genus in the ‘048 Provisional fails to provide written description suppor
ENTA PFE
sharkey1 sharkey1 7 minutes ago
BS rack 186, but I am glad to see you spending a lot of useless vile energy trashing people on this board,
takes a lot of time to come up the stuff you post.
ELTP
ddls ddls 7 minutes ago
Buy: 0 - Neutral: 129,911 - Sell: 13,816,260 😭

Friday 12/27/24
BIEL
yman yman 8 minutes ago
Hey Mungo did you try contacting the Ant man? If he thinks he has a real chance with his case, he may be interested in more shares. How many shares are you talking about, I might be interested.
NNLX
Implanting Implanting 8 minutes ago
O.K. what's being discussed in the interview IMO will be the MAJOR catalyst for a much higher gold price in the next few years. It's geopolitical in nature and it's most likely going to involve the U.S. and China in a military conflict of some sort.

The fellow in the interview is ver
FFMGF
Filterthenoise Filterthenoise 9 minutes ago
Im a shareholder
RNVA
RKMKE RKMKE 9 minutes ago
Pumpers are getting out control with their rotten theories... so tell us whats has been accomplished and what cam to fruition???


WDLF
dstock07734 dstock07734 11 minutes ago
Mike,

Enlighten me why the unpublished paper seems like having conclusion different from the one published on Nature five years ago.

The published paper states that neoadjuvant therapy can double OS in comparison of adjuvant treatment while the unpublished paper claims
NWBO
nyt nyt 12 minutes ago
All the news the emu promised to start presenting........ ITS TOO MUCH! STOP! I CAN'T TAKE IT ALL.....HALP! AAAaaaargh
VPLM
sokol sokol 12 minutes ago
The J.P. Morgan Healthcare Conference is widely regarded as the premier event in the healthcare industry. It is the largest and most influential healthcare investment symposium, attracting top executives, investors, and innovators from over 400 organizations globally. Known for shaping industry tren
AVXL
al44 al44 13 minutes ago
An easier way to show illegals the door

By Philip Lillingston

A recent article in the Wall Street Journal by a Jess Bravin reported that attorneys general of many blue states are not going to give up quietly when Donald Trump, as president, begins to honor his election
Vexari Vexari 14 minutes ago
Gaining strength

Against the cartels grip

Tide is turning

Retribution

Is near
PFE
glenn1919 glenn1919 15 minutes ago
cocp............................https://stockcharts.com/h-sc/ui?s=cocp&p=D&yr=0&mn=2&dy=12&id=p84071410134
meixatech meixatech 15 minutes ago
Pharmacological modulation of hypoxia-induced respiratory neuroplasticity

Sara Turner , Kristi Streeter , John Greer, Gordon S Mitchell, David D Fuller

PMCID: PMC6155458 NIHMSID: NIHMS987117 PMID: 29197629
Respir Physiol Neurobiol. 2017 Nov 29;256:4–14. doi: 10
RSPI
CaptainObvious CaptainObvious 15 minutes ago
I'll keep mine at .57 since we are talking the first full day after approval, and no other announcements.
NWBO
BullNBear52 BullNBear52 16 minutes ago
Mets have big Alonso decision on their hands
December 27th, 2024
Anthony DiComo

https://www.mlb.com/news/mets-biggest-question-before-2025-spring-training

By now Alonso has to be feeling unloved after the Mets signed Soto and they still haven't made a dece
glenn1919 glenn1919 17 minutes ago
cocp...........................................https://stockcharts.com/h-sc/ui?s=cocp&p=W&b=5&g=0&id=p86431144783
COCP
Genz2 Genz2 17 minutes ago
https://www.cnbc.com/amp/2024/12/28/why-microsoft-amazon-google-and-meta-are-betting-on-nuclear-power.html

Now why aren’t these companies betting on the unlimited supply of solar and mega packs with Elon!! Are we going to have another nuclear meltdown and destroy the environment?? E
gawti88 gawti88 18 minutes ago
lol bro, insane how big this company has grown. lol.... 60k+ days now haha man i remember they were doing 60k sales in a month LOL.

60k months are now 60k days. This is probably a top 5 otc pick. Get ready.
CEOS
al44 al44 19 minutes ago
Your neighbor is deep in debt

By Kevin Finn

What would you say about a family of four who earns $44,000 per year and spends $61,000? Crazy, right? It gets worse. The family is $362,000 in debt, and that debt alone is generating $10,000 a year in interest.
Clark6290 Clark6290 20 minutes ago
His name is Judge Lamberth. I fail to understand why all the derogatory names for him, think the emoji 🤔 fella started it
FNMA
flipper44 flipper44 20 minutes ago
Again, FeMike’s survey question is asked under the synthetic given that nothing else will be announced when (likely) approval is announced.

I agree with FeMike’s point that approval should not be announced in isolation.
NWBO has one temporary advantage right now. It held bac
NWBO
Dorick Dorick 20 minutes ago
Sorry to hear that, Mr. PC. Get well soon!
FLCX

Your Recent History

NASDAQ
CLBS
Caladrius Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads